Author's Take

No articles were found with this tag.

Targeting hepatic kisspeptin receptors and nonalcoholic fatty liver disease
In this episode, Stephania Guzman explains that this study establishes the kisspeptin receptor as a therapeutic target to treat nonalcoholic fatty liver disease...
Published May 18, 2022
Author's Take
Food addiction vulnerability in mice and humans and miRNA signatures
In this episode, Rafael Maldonado and Elena Martín-García explain how similar patterns of miRNAs signatures of food addiction vulnerability are present in animals and humans...
Published May 16, 2022
Author's Take
Efferocytosis induces VEGFC to improve cardiac injury and inflammation
In this episode, Guillermo Oliver and Ed Thorp discuss how cardiac VEGF-C is sourced from macrophages after efferocytosis to ameliorate cardiac injury and inflammation...
Published May 2, 2022
Author's Take
Gut-derived bacterial toxins and HIV-1 infection
In this episode, Souheil-Antoine Younes explains that their findings propose that toxic solutes from the gut bacterial flora may impair CD4+ T cell recovery during ART and may contribute to CD4+ T cell lymphopenia characteristic of INRs...
Published May 2, 2022
Author's Take
Tertiary lymphoid tissue expansion and kidney injury are promoted by CD153/CD30 signaling
In this episode, Motoko Yanagita and Yuki Sato explain that CD153-CD30 signaling is required for tertiary lymphoid tissue expansion and represents a therapeutic target for kidney diseases in the elderly...
Published January 31, 2022
Author's Take
COVID-19 outcomes in African American patients using ACE inhibitors/angiotensin receptor blockers
In this episode, Li Li explains that in-hospital use of angiotensin receptor blockers was associated with a significant reduction in mortality among COVID-19-positive African American patients...
Published December 3, 2021
Author's Take
Complement C3 inhibitor AMY-101 in adults with periodontal inflammation – clinical trial
In this episode, the authors explain that local delivery of the complement C3 inhibitor AMY-101 in patients with gingivitis was safe, well tolerated, and led to significant and sustained reduction of clinical indices of gingival inflammation...
Published December 1, 2021
Author's Take
Hallmarks of the immunometabolic imbalance in COVID-19
In this episode, Marina Kreutz and colleagues discuss how their findings provide evidence of an immunometabolic dysregulation in COVID-19, which can be mitigated by dexamethasone treatment...
Published November 19, 2021
Author's Take
CHI3L1 regulates PD-L1 and anti–CHI3L1–PD-1 antibody elicits synergistic antitumor responses
In this episode, Jack Elias explains that these studies demonstrate that CHI3L1 contributes to pulmonary metastasis by regulating PD-1-PD-L-1 axis, and simultaneous targeting of CHI3L1 and PD-1/PD-L1 axis elicits synergistic antitumor responses...
Published November 1, 2021
Author's Take
Desmin degradation and dilatation in hiPSC-derived engineered heart tissues
In this episode, Peter van der Meer and Mathilde Vermeer explain the pathological role of KLHL24 methionine start-codon mutations in the development of dilated cardiomyopathy using hiPSC-derived dynamically loaded engineered heart tissues...
Published September 3, 2021
Author's Take
Advertisement